search
Back to results

Comparison of Nutritional Products for People With Type 2 Diabetes

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
enteral nutritional formula
Diabetes specific enteral product
Sponsored by
Abbott Nutrition
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed and dated informed consent form
  • Type 2 diabetes
  • 18 to 75 years of age
  • Male or non-pregnant, non-lactating female, at least 6 weeks postpartum
  • If female is of childbearing potential, is practicing birth control
  • BMI greater than or equal to 18.5 kg/m2 and less than 40.0 kg/m2
  • Medications, such as antihyperglycemic or thyroid medications or hormone therapy, have been maintained at a constant dosage for at least two months prior to screening visit

Exclusion Criteria:

  • Uses exogenous insulin for glucose control
  • Type 1 diabetes
  • History of diabetic ketoacidosis
  • Current infection; has received corticosteroid treatment in the last 3 months, or has had surgery or received antibiotics in the last 3 weeks
  • Active malignancy
  • Significant cardiovascular event less than 12 weeks prior to study entry
  • End stage organ failure or is status post organ transplant
  • Has an active metabolic, hepatic, or gastrointestinal disease that may interfere with nutrient absorption, distribution, metabolism, or excretion excluding diabetes
  • Chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV
  • Taking any herbals, dietary supplements or medications, other than antihyperglycemic medications during the past four weeks that could profoundly affect blood glucose
  • Fainted or experienced other adverse reactions in response to blood collection prior to this study
  • Has clotting or bleeding disorders
  • Allergic or intolerant to any ingredient found in the study products
  • Participant in a concomitant trial that conflicts with this study

Sites / Locations

  • Provident Clinical Research and Consulting, Inc.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

#1

#2

Arm Description

Diabetes specific enteral product

Standard enteral feeding

Outcomes

Primary Outcome Measures

Positive area under the curve (AUC) for plasma glucose and mean glucose level

Secondary Outcome Measures

Adjusted peak values for plasma glucose and serum insulin concentrations and positive AUC for serum insulin concentration

Full Information

First Posted
August 21, 2007
Last Updated
July 2, 2008
Sponsor
Abbott Nutrition
search

1. Study Identification

Unique Protocol Identification Number
NCT00520065
Brief Title
Comparison of Nutritional Products for People With Type 2 Diabetes
Official Title
Comparison of Nutritional Products for People With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
August 2007
Overall Recruitment Status
Completed
Study Start Date
August 2007 (undefined)
Primary Completion Date
October 2007 (Actual)
Study Completion Date
November 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Abbott Nutrition

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Part A: To compare the glucose and insulin responses of a standard tube feeding product to that of a diabetes-specific tube feeding product in individuals with type 2 diabetes. Part B: To compare the glucose response of a standard tube feeding product to that of a diabetes-specific tube feeding product when consumed by individuals with type 2 diabetes as a sole source of nutrition.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
33 (Actual)

8. Arms, Groups, and Interventions

Arm Title
#1
Arm Type
Experimental
Arm Description
Diabetes specific enteral product
Arm Title
#2
Arm Type
Active Comparator
Arm Description
Standard enteral feeding
Intervention Type
Other
Intervention Name(s)
enteral nutritional formula
Intervention Description
Meal glucose tolerance test
Intervention Type
Other
Intervention Name(s)
Diabetes specific enteral product
Intervention Description
Meal Glucose tolerance test
Primary Outcome Measure Information:
Title
Positive area under the curve (AUC) for plasma glucose and mean glucose level
Time Frame
240 minutes
Secondary Outcome Measure Information:
Title
Adjusted peak values for plasma glucose and serum insulin concentrations and positive AUC for serum insulin concentration
Time Frame
240 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed and dated informed consent form Type 2 diabetes 18 to 75 years of age Male or non-pregnant, non-lactating female, at least 6 weeks postpartum If female is of childbearing potential, is practicing birth control BMI greater than or equal to 18.5 kg/m2 and less than 40.0 kg/m2 Medications, such as antihyperglycemic or thyroid medications or hormone therapy, have been maintained at a constant dosage for at least two months prior to screening visit Exclusion Criteria: Uses exogenous insulin for glucose control Type 1 diabetes History of diabetic ketoacidosis Current infection; has received corticosteroid treatment in the last 3 months, or has had surgery or received antibiotics in the last 3 weeks Active malignancy Significant cardiovascular event less than 12 weeks prior to study entry End stage organ failure or is status post organ transplant Has an active metabolic, hepatic, or gastrointestinal disease that may interfere with nutrient absorption, distribution, metabolism, or excretion excluding diabetes Chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV Taking any herbals, dietary supplements or medications, other than antihyperglycemic medications during the past four weeks that could profoundly affect blood glucose Fainted or experienced other adverse reactions in response to blood collection prior to this study Has clotting or bleeding disorders Allergic or intolerant to any ingredient found in the study products Participant in a concomitant trial that conflicts with this study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kevin C. Maki, PhD
Organizational Affiliation
Provident Clinical Research and Consulting, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Provident Clinical Research and Consulting, Inc.
City
Bloomington
State/Province
Indiana
ZIP/Postal Code
47403
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
20470226
Citation
Alish CJ, Garvey WT, Maki KC, Sacks GS, Hustead DS, Hegazi RA, Mustad VA. A diabetes-specific enteral formula improves glycemic variability in patients with type 2 diabetes. Diabetes Technol Ther. 2010 Jun;12(6):419-25. doi: 10.1089/dia.2009.0185.
Results Reference
derived

Learn more about this trial

Comparison of Nutritional Products for People With Type 2 Diabetes

We'll reach out to this number within 24 hrs